Back to Authors

Kaufer, Daniel

https://orcid.org/0000-0002-9629-3455

A5051629477 | I114027177

Mayo Clinic

University of North Carolina at Chapel Hill

Citations 35

[P2–303]: ADVANCING RESEARCH AND TREATMENT IN FRONTOTEMPORAL LOBAR DEGENERATION (ARTFL) NORTH AMERICAN RARE DISEASE CLINICAL RESEARCH CONSORTIUM: PROGRESS AND CHARACTERIZATION OF INITIAL PARTICIPANTS

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_15 | Pages: No page available

10.1016/j.jalz.2017.06.956

Arguing against the proposed definition changes of PD

Movement Disorders | August 5, 2016 | Volume: 31 | Issue: 11 | Pages: 1619-1622

10.1002/mds.26721 | PMID 27492190

ABSTRACT As members of the Lewy Body Dementia Association Scientific Advisory Council, we aim to address some of the issues raised in the article titled “Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease.” In particular, we suggest that the 1‐year rule distinguishing Parkinson's disease dementia from dementia with Lewy bodies is worth maintaining because it serves an important purpose in clinical practice and clinical and basic science research and when helping the lay community understand the complexity of these different clinical phenotypes. Furthermore, we believe that adding an additional diagnostic label, “PD (dementia with Lewy bodies subtype),” will confuse rather than clarify the distinction between dementia with Lewy bodies and PD or PD dementia, and will not improve management or expedite therapeutic development. We present arguments supporting our contentions. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
P3‐309: Advancing research and treatment of frontotemporal lobar degeneration (ARTFL): Preparing for clinical trials for ftld in north america

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_16 | Pages: No page available

10.1016/j.jalz.2015.06.1683

Improving clinical cognitive testing

Neurology | July 11, 2015 | Volume: 85 | Issue: 10 | Pages: 910-918

10.1212/wnl.0000000000001763 | PMID 26163433

P2‐403: A randomized, multicenter, placebo controlled trial of memantine for behavioral variant FTD and semantic variant PPA

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_11 | Pages: No page available

10.1016/j.jalz.2012.05.1113